This article is more than 5 years old. Information may no longer be current.

IAVI, Selexis expand collaboration for development of HIV vaccines

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

Selexis SA announced it has expanded its collaboration with the International AIDS Vaccine Initiative to develop high-performance research cell banks for the manufacturing of multiple HIV envelope proteins to induce the generation of neutralizing antibodies against HIV via vaccination.

“Manufacturing of engineered HIV proteins in consistent quantity and quality is critical for further development of promising vaccine candidates toward early clinical testing,” Labeeb Abboud, senior vice president of business development at the International AIDS Vaccine Initiative (IAVI), said in a press release. “We are pleased to extend our collaboration with Selexis to expedite the development of broadly effective vaccines that will be needed to help end the AIDS epidemic.”

Under the agreement, Selexis will manufacture the proteins engineered by IAVI scientists. Selexis previously worked with IAVI on another engineered HIV envelope protein, developed by IAVI’s Neutralizing Antibody Center at The Scripps Research Institute. The goal was to increase cell line productivity using the Selexis CHO-Mplus Libraries, which resulted in more than 3,000% improvement in expression titers over conventional approaches, the release said.

“Selexis and IAVI continue to build upon the success of the initial collaboration to further advance HIV vaccine research and development,” Yemi Onakunle, PhD, vice president of licensing and business development at Selexis, said in the release. “HIV envelope proteins are difficult to express and manufacture with consistent high quality and in high quantities.

“At Selexis, our goal is to translate innovation and scientific research into lifesaving medications. It is therefore incredibly rewarding to have the opportunity to leverage our production cell lines in the development of vaccines against HIV, a viral disease of such high unmet need.”

Financial terms were not disclosed, according to the release.

Disclosures: Onakunle is employed by Selexis SA. Abboud is employed by the International AIDS Vaccine Initiative.